Positive data from Ascendis Pharma
A candidate drug from Danish biotech company Ascendis Pharma has shown promise in a phase II study, an interim analysis of the data suggests.
BY STEFAN SINGH KAILAY
The string of good news continues for Denmark-based biotech Ascendis Pharma, which recently brought in USD 300 million from investors and is also rumored to be gearing up for an IPO, as the company has shown solid data from a clinical study.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Mysterious Mikkelsen does not receive mails
For abonnenter
Acendis Pharma raises USD 60 million
For abonnenter
Danish company hires yet another American exec
For abonnenter
